Tags

Type your tag names separated by a space and hit enter

A mechanistic multicentre, parallel group, randomised placebo-controlled trial of mesalazine for the treatment of IBS with diarrhoea (IBS-D).
Gut. 2016 Jan; 65(1):91-9.Gut

Abstract

INTRODUCTION

Immune activation has been reported in the mucosa of IBS patients with diarrhoea (IBS-D), and some small studies have suggested that mesalazine may reduce symptoms. We performed a double-blind, randomised placebo-controlled trial of 2 g mesalazine twice daily versus placebo for 3 months in patients with Rome III criteria IBS-D. Primary outcome was daily average stool frequency during weeks 11-12; secondary outcomes were abdominal pain, stool consistency, urgency and satisfactory relief of IBS symptoms.

METHODS

Participants were randomised after a 2-week baseline stool diary. All participants completed a 12-week stool diary and at the end of each week recorded the presence of 'satisfactory relief of IBS symptoms'.

RESULTS

136 patients with IBS-D (82 women, 54 men) were randomised, 10 patients withdrew from each group. Analysis by intention to treat showed the daily average stool frequency during weeks 11 and 12 were mean (SD), 2.8 (1.2) in mesalazine and 2.7 (1.9) in the placebo group with no significant group difference, (95% CI) 0.1 (-0.33 to 0.53), p=0.66. Mesalazine did not improve abdominal pain, stool consistency nor percentage with satisfactory relief compared with placebo during the last two-weeks follow-up.

CONCLUSIONS

This study does not support any clinically meaningful benefit or harm of mesalazine compared with placebo in unselected patients with IBS-D. More precise subtyping based on underlying disease mechanisms is needed to allow more effective targeting of treatment in IBS.

TRIAL REGISTRATION NUMBER

NCT01316718.

Authors+Show Affiliations

NIHR Nottingham Digestive Diseases Biomedical Research Unit, University of Nottingham, Nottingham, UK.Nottingham Clinical Trials Unit, University of Nottingham, Nottingham, UK.Nottingham Clinical Trials Unit, University of Nottingham, Nottingham, UK.Neurogastroenterology Unit, Wythenshawe Hospital, Manchester, UK.NIHR Nottingham Digestive Diseases Biomedical Research Unit, University of Nottingham, Nottingham, UK.NIHR Nottingham Digestive Diseases Biomedical Research Unit, University of Nottingham, Nottingham, UK.Immunopharmacology Group, University of Southampton, Southampton General Hospital, Southampton, UK.FRAME laboratory, University of Nottingham, Nottingham, UK.Neurogastroenterology Unit, Wythenshawe Hospital, Manchester, UK.Immunopharmacology Group, University of Southampton, Southampton General Hospital, Southampton, UK.Department of Histopathology, Nottingham University Hospital Trusts, Nottingham, UK.Nottingham Clinical Trials Unit, University of Nottingham, Nottingham, UK.NIHR Nottingham Digestive Diseases Biomedical Research Unit, University of Nottingham, Nottingham, UK.

Pub Type(s)

Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

25765462

Citation

Lam, Ching, et al. "A Mechanistic Multicentre, Parallel Group, Randomised Placebo-controlled Trial of Mesalazine for the Treatment of IBS With Diarrhoea (IBS-D)." Gut, vol. 65, no. 1, 2016, pp. 91-9.
Lam C, Tan W, Leighton M, et al. A mechanistic multicentre, parallel group, randomised placebo-controlled trial of mesalazine for the treatment of IBS with diarrhoea (IBS-D). Gut. 2016;65(1):91-9.
Lam, C., Tan, W., Leighton, M., Hastings, M., Lingaya, M., Falcone, Y., Zhou, X., Xu, L., Whorwell, P., Walls, A. F., Zaitoun, A., Montgomery, A., & Spiller, R. (2016). A mechanistic multicentre, parallel group, randomised placebo-controlled trial of mesalazine for the treatment of IBS with diarrhoea (IBS-D). Gut, 65(1), 91-9. https://doi.org/10.1136/gutjnl-2015-309122
Lam C, et al. A Mechanistic Multicentre, Parallel Group, Randomised Placebo-controlled Trial of Mesalazine for the Treatment of IBS With Diarrhoea (IBS-D). Gut. 2016;65(1):91-9. PubMed PMID: 25765462.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A mechanistic multicentre, parallel group, randomised placebo-controlled trial of mesalazine for the treatment of IBS with diarrhoea (IBS-D). AU - Lam,Ching, AU - Tan,Wei, AU - Leighton,Matthew, AU - Hastings,Margaret, AU - Lingaya,Melanie, AU - Falcone,Yirga, AU - Zhou,Xiaoying, AU - Xu,Luting, AU - Whorwell,Peter, AU - Walls,Andrew F, AU - Zaitoun,Abed, AU - Montgomery,Alan, AU - Spiller,Robin, Y1 - 2015/03/12/ PY - 2015/01/06/received PY - 2015/02/03/accepted PY - 2015/3/14/entrez PY - 2015/3/15/pubmed PY - 2016/4/5/medline KW - 5-AMINOSALICYLIC ACID (5-ASA) KW - DIARRHOEA KW - IRRITABLE BOWEL SYNDROME SP - 91 EP - 9 JF - Gut JO - Gut VL - 65 IS - 1 N2 - INTRODUCTION: Immune activation has been reported in the mucosa of IBS patients with diarrhoea (IBS-D), and some small studies have suggested that mesalazine may reduce symptoms. We performed a double-blind, randomised placebo-controlled trial of 2 g mesalazine twice daily versus placebo for 3 months in patients with Rome III criteria IBS-D. Primary outcome was daily average stool frequency during weeks 11-12; secondary outcomes were abdominal pain, stool consistency, urgency and satisfactory relief of IBS symptoms. METHODS: Participants were randomised after a 2-week baseline stool diary. All participants completed a 12-week stool diary and at the end of each week recorded the presence of 'satisfactory relief of IBS symptoms'. RESULTS: 136 patients with IBS-D (82 women, 54 men) were randomised, 10 patients withdrew from each group. Analysis by intention to treat showed the daily average stool frequency during weeks 11 and 12 were mean (SD), 2.8 (1.2) in mesalazine and 2.7 (1.9) in the placebo group with no significant group difference, (95% CI) 0.1 (-0.33 to 0.53), p=0.66. Mesalazine did not improve abdominal pain, stool consistency nor percentage with satisfactory relief compared with placebo during the last two-weeks follow-up. CONCLUSIONS: This study does not support any clinically meaningful benefit or harm of mesalazine compared with placebo in unselected patients with IBS-D. More precise subtyping based on underlying disease mechanisms is needed to allow more effective targeting of treatment in IBS. TRIAL REGISTRATION NUMBER: NCT01316718. SN - 1468-3288 UR - https://www.unboundmedicine.com/medline/citation/25765462/A_mechanistic_multicentre_parallel_group_randomised_placebo_controlled_trial_of_mesalazine_for_the_treatment_of_IBS_with_diarrhoea__IBS_D__ DB - PRIME DP - Unbound Medicine ER -